Pharming Group FY2025 EPS Estimate Raised by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities research analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for Pharming Group in a note issued to investors on Wednesday, February 4th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.10 for the year, up from their previous forecast of $0.02. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s FY2026 earnings at $0.49 EPS and FY2027 earnings at $0.66 EPS.

Several other research firms have also commented on PHAR. Zacks Research lowered Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen upgraded Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pharming Group in a research note on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Pharming Group currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Pharming Group Trading Up 0.3%

Pharming Group stock opened at $16.09 on Monday. Pharming Group has a 1 year low of $7.50 and a 1 year high of $21.34. The firm’s 50-day moving average is $17.75 and its 200-day moving average is $15.36. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. The company has a market cap of $1.13 billion, a P/E ratio of -1,607.39 and a beta of -0.01.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.05. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The firm had revenue of $97.30 million during the quarter, compared to analyst estimates of $98.22 million.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.